Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 1, 2011, Pages 1-10

  Danese, S ^a   Fiorino, G ^a   Reinisch, W ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADALIMUMAB ANTIBODY; ALBUMIN; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CERTOLIZUMAB PEGOL; DNA ANTIBODY; DRUG ANTIBODY; HYDROCORTISONE; INFLIXIMAB; INFLIXIMAB ANTIBODY; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; USTEKINUMAB;

ALBUMIN BLOOD LEVEL; ANTIBODY PRODUCTION; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MONOTHERAPY; PREMEDICATION; PRIORITY JOURNAL; PUVA; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

EID: 79958136275     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04679.x     Document Type: Review

References (54)

1. Rutgeerts P, Vermeire S, Van Assche G,. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136: 1182-97.
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76. (Pubitemid 41770166)
3. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 2010; 4: 28-62.
4. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85. (Pubitemid 38252535)
5. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
6. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-50. (Pubitemid 47080388)
7. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8. (Pubitemid 36204954)
8. Hanauer S, Feagan B, Lichtenstein G, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
9. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
10. Colombel JF, Panaccione R, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010; 31: 1296-309.
11. Panés J, Gisbert JP,. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-7.
12. Feagan BG, Rutgeerts P, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13. (Pubitemid 38182297)
13. Sono K, Yamada A, Hosoe N, Takada N, Suzuki Y,. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis 2010; 16: 1898-904.
14. Xu Z, Seitz K, Fasanmade A, et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 2008; 48: 681-95. (Pubitemid 351713154)
15. Pink AE, Fonia A, Allen MH, Smith CH, Barker JN,. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol 2010; 162: 780-5.
16. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003; 125: 32-9. (Pubitemid 36799104)
17. Maser EA, Villela R, Silverberg MS, Greenberg GR,. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-54. (Pubitemid 44512213)
18. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab therapy in acute ulcerative colitis. Gut 2010; 59: 49-54.
19. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-9. (Pubitemid 34620190)
20. Kopylov U, Mantzaris GJ, Katsanos KH, et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther 2011; 33: 349-57.
21. Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM,. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010; 48: 297-308.
22. Tabrizi MA, Tseng CML, Roskos LK,. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006; 11: 81-8. (Pubitemid 43227856)
23. Ainsworth MA, Bendtzen K, Brynskov J,. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008; 103: 944-8. (Pubitemid 351501078)
24. Maini RN, Breedveld FC, Kalden JR, et al. Therapy efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63. (Pubitemid 28459913)
25. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-8. (Pubitemid 351790744)
26. Johnson GJ, Cosnes J, Mansfield JC,. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2005; 21: 921-31. (Pubitemid 40529727)
27. Triantafillidis JK, Mantzaris G, Karagiannis J, et al. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab. Rev Med Chir Soc Med Nat Iasi 2010; 114: 85-90.
28. Loftus EV Jr, Pan X, Zurawski P, Mulani P, Chao J,. Patterns and predictors of dosage increase in patients treated with adalimumab for Crohn's disease in the United States. J Crohns Colitis 2009; 3: S24.
29. Tracey D, Cosnes J, Cattan S, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-79.
30. van Baarsen LG, Wijbrandts CA, Gerlag DM, et al. Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis. Genes Immun 2010; 11: 622-9.
31. Lindberg J, Wijbrandts CA, van Baarsen LG, et al. The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis. PLoS ONE 2010; 5: e11310.
32. Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009; 58: 1612-9.
33. Arijs I, Quintens R, Van Lommel L, et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010; 16: 2090-8.
34. Arijs I, De Hertogh G, Lemaire K, et al. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS ONE 2009; 4: e7984.
35. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24. (Pubitemid 36389794)
36. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-31. (Pubitemid 47300423)
37. Mantzaris GJ, Viazis N, Petraki K, et al. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab. Eur J Gastroenterol Hepatol 2009; 21: 1042-8.
38. Oussalah A, Chevaux JB, Fay R, et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol 2010; 105: 1142-9.
39. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
40. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-40.
41. Sandborn WJ, Colombel JF, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011; 17: 141-51.
42. Sandborn WJ, Schreiber S, Hanauer SB, et al. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol 2010; 8: 696-702.
43. Lichtenstein GR, Thomsen O., Schreiber S, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 2010; 8: 600-9.
44. Kaplan GG, Hur C, Korzenik J, Sands BE,. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007; 26: 1509-20. (Pubitemid 350178810)
45. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38. (Pubitemid 351650483)
46. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
47. Ma C, Panaccione R, Heitman SJ, et al. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther 2009; 30: 977-86.
48. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-9.
49. Sandborn WJ, Abreu MT, D'Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010; 8: 688-95.
50. Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010; 31: 92-101.
51. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-25. (Pubitemid 41565956)
52. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135: 1130-41.
53. Available at:.
54. Abreu MT, von Tirpitz C, Hardi R, et al. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis 2009; 15: 829-36.